The Cannigma
MARCH 7, 2021
People may not have to microdose psychedelics to feel their wellbeing benefits, according to a new study – they just have to believe they’ve microdosed them. Published in eLife , the new study found that participants who took placebos often reported the same beneficial effects as those that actually microdosed psychedelic substances.
Cannabis Law Report
JULY 25, 2022
million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD). The state agency grant funding followed the successful completion of a phase 1 clinical trial in 80 healthy participants.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Joint Blog
NOVEMBER 15, 2021
While over the last few years, microdosing has become extremely popular, the act of microdosing has been recommended by experts for at least two decades. There are also many different substances that you can microdose, from psilocybin mushrooms to delta-8. In this article, we are going to cover microdose of legal substances.
Cannabis Law Report
MAY 10, 2023
However, a company may be in possession of the most healing psychedelic compound in the world, but unless they can prove it through the clinical trial process, their superior medicine will mean little. Yes, of course, it matters greatly who has the most effective medical psychedelic molecule in specific circumstances.
Cannabis Law Report
JULY 9, 2022
Desperate to find any solution, she tried microdosing psilocybin mushrooms after researching the practice online. For Thornton, however, microdosing psilocybin mushrooms was a question of life or death. “I I decided to try microdosing psilocybin for depression because nothing else was working for me,” explains Thornton. “I
Cannabis Law Report
DECEMBER 2, 2021
(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.
Cannabis Law Report
FEBRUARY 14, 2020
a Canadian biotech firm, is entering Phase II clinical trials for two experimental treatments. According to its website, one trial involves an ibogaine-derived drug for treating opioid addiction. The other trial will test LSD microdosing as an ADHD treatment. Mind Medicine, Inc. ,
Expert insights. Personalized for you.
120 
Let's personalize your content